CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Jilin Zixin Pharmaceutical Ind. Co., Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Jilin Zixin Pharmaceutical Ind. Co., Ltd
No.137 Dongtoudao Street
Nanguan District
Phone: +86 43181916633p:+86 43181916633 CHANGCHUN, JLN  130041  China Fax: +86 43188698366f:+86 43188698366
This company is no longer actively traded on any major stock exchange.
Business Summary
JILIN ZIXIN PHARMACEUTICAL INDUSTRIAL CO., LTD is a China-based company, principally engaged in the research and development, production and distribution of traditional Chinese patent drugs and ginseng products. The Company operates its businesses through three segments. The Traditional Chinese Patent Drugs segment mainly provides traditional Chinese patent drugs for the treatment of rheumatoid immunity, ear-nose-throat (ENT), urinary system cardiovascular, hepatobiliary and digestive diseases. The Ginseng Products segment is engaged in the provision of deep processing products and rough-wrought products, including white ginseng products, red ginseng products, drinks and candied fruits. The Gene Sequencing segment is engaged in the research and development, manufacture and distribution of gene sequencing machines and supporting reagents.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202312/31/2022Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, General Manager, Acting Secretary of the Board XiangjinMeng 46 6/7/2023 7/28/2022
Chief Financial Officer HongfengLu 53 5/10/2023 5/10/2023
Deputy General Manager, Director MingHan 49 4/24/2018 4/2/2018
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 842 (As of 12/31/2022)
Outstanding Shares: 1,280,759,826 (As of 3/31/2023)
Shareholders: 110,982
Stock Exchange: SHE
Fax Number: +86 43188698366


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 18, 2024